Carfizome 60mg Injection Abu Dhabi | Top Pharma Exporter from India

Carfizome 60mg Injection: Advanced Proteasome Inhibition for Relapsed Multiple Myeloma

Are you searching for a reliable Carfizome 60 mg injection exporter from India? Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of high-intensity oncology therapeutics. We serve critical healthcare markets in the UK (London), USA, UAE (Abu Dhabi), Australia, and South Africa, ensuring that advanced hematological treatments are accessible through a streamlined B2B pharmaceutical supply chain.

Detailed Product Overview: What is Carfizome 60mg?

Carfizome 60mg is a prescription-strength injectable medication containing Carfilzomib. It is a second-generation Proteasome Inhibitor designed to treat patients with multiple myeloma—a type of white blood cell cancer that accumulates in the bone marrow.

Carfizome is engineered to be more selective and potent than earlier proteasome inhibitors, offering a critical therapeutic option for patients whose cancer has returned (relapsed) or has stopped responding to other treatments (refractory).

Primary Therapeutic Indications:

Carfizome 60 mg is clinically indicated for:

• Relapsed or Refractory Multiple Myeloma: As a monotherapy for patients who have received one or more previous lines of therapy.

• Combination Therapy: Frequently used in combination with Dexamethasone or with Lenalidomide and Dexamethasone to improve progression-free survival rates.

• Second-Line Treatment: Targeted specifically at patients who have already undergone treatment with proteasome inhibitors like Bortezomib and immunomodulatory agents.

Mechanism of Action: How Carfizome Works: 

The efficacy of Carfizome lies in its ability to disrupt the "waste disposal" system of cancer cells.

1. Proteasome Blockade: The drug irreversibly binds to the 20S proteasome, an enzyme complex that breaks down damaged or unneeded proteins within a cell.

2. Protein Overload: By blocking the proteasome, Carfizome causes an excessive buildup of proteins within the myeloma cell.

3. Apoptosis (Cell Death): This protein "congestion" triggers a stress response that forces the cancer cell to undergo programmed cell death (apoptosis), effectively shrinking tumors and clearing the bone marrow of malignant cells.

Administration and Dosage

• Route: Administered strictly as an Intravenous (IV) infusion by a healthcare professional.

• Hydration Protocol: Patients must be adequately hydrated before and after each dose to protect kidney function and prevent Tumor Lysis Syndrome (TLS).

• Schedule: Typically administered on two consecutive days each week for three weeks, followed by a rest period. The exact cycle depends on whether it is used as a single agent or in combination therapy.

Common Side Effects & Safety Monitoring :

Medical professionals should monitor patients for:

• Cardiovascular Events: Blood pressure spikes or heart failure symptoms.

• Respiratory Issues: Shortness of breath (dyspnea).

• Hematological Changes: Fatigue due to anemia or increased bruising due to low platelet counts (thrombocytopenia).

• Kidney Function: Regular monitoring of serum creatinine levels is vital.

Why Source Carfizome 60 mg from Ernest Oncology?

• Cold Chain Logistics: Expert handling of temperature-sensitive injectables for delivery to USA, UK, UAE, Australia, and South Africa. 

• Authentic Sourcing: Direct procurement from GMP-certified facilities, maintaining the highest standards for an exporter from India.

• Bulk Supply Stability: We ensure a consistent supply of 60mg vials to prevent treatment interruptions for hospitals and clinics.

• Global B2B Support: Specialized pricing and documentation for international pharmaceutical distributors.